

Amelia Insa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4042062/publications.pdf>

Version: 2024-02-01

18
papers

8,399
citations

932766

10
h-index

1058022

14
g-index

18
all docs

18
docs citations

18
times ranked

8802
citing authors

#	ARTICLE	IF	CITATIONS
1	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103538.	2.0	13
2	Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). <i>Journal of Clinical Oncology</i> , 2022, 40, 2924-2933.	0.8	127
3	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	1.7	26
4	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. <i>Cancer Medicine</i> , 2021, 10, 5878-5888.	1.3	11
5	Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2021, 23, 2560-2567.	1.2	7
6	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5878-5890.	3.2	30
7	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
8	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). <i>Lung Cancer</i> , 2020, 150, 62-69.	0.9	15
9	In the literature: December 2019. <i>ESMO Open</i> , 2020, 5, e000642.	2.0	0
10	Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1413-1422.	5.1	475
11	In the literature: February 2019. <i>ESMO Open</i> , 2019, 4, e000490.	2.0	0
12	Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. <i>Clinical Lung Cancer</i> , 2017, 18, 178-188.e4.	1.1	5
13	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167.	0.9	81
14	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
15	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1074-1074.	0.8	0
16	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 1160-1168.	3.2	292
17	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	13.9	2,213
18	Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 67-78.	1.1	156